Abstract

Alendronate 70-mg/75-mL Drinkable Formulation

Author(s): Allen Loyd V Jr

Issue: Nov/Dec 2016 - Volume 20, Number 6

Page(s): 504

Download in electronic PDF format for $75
  • Alendronate 70-mg/75-mL Drinkable Formulation Page 1

Abstract

A formulation for preparing Alendronate 70-mg/75-mL Drinkable Formulation. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

  • formulation
  • alendronate
  • osteoporosis
  • bone mass
  • postmenopausal women

Related Categories

  • FORMULATIONS
  • ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE
  • MUSCULOSKELETAL DISORDERS

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Nov/Dec 2016
Pg. 504
Alendronate 70-mg/75-mL Drinkable Formulation
Author(s): Allen Loyd V Jr
Nov/Dec 2004
Pg. 462-465
Basics of Compounding for Cough
Author(s): Allen Loyd V Jr
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
May/Jun 2022
Pg. 232
Alendronate Sodium 1% Topical Dental Gel
Author(s): Allen Loyd V Jr
Jan/Feb 2004
Pg. 16-21
Androgen Deficiency in Women: Understanding the Science, Controversy and Art of Treating Our Patients - Part 1
Author(s): Cutter Christopher B
Jan/Feb 2004
Pg. 10-14
Women's Oral Health: Is There a Hormonal Link?
Author(s): Preckshot John
Sep/Oct 2003
Pg. 330-338
A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2
Author(s): Gillson George R, Zava David T
Mar/Apr 2023
Pg. 108-112
Vulvovaginal Symptoms in a Postmenopausal Woman: A Case Study
Author(s): Lima Ramona, Gonzalez Mark A, Urwin Craig, Jean Linda, Carvalho Maria, Banov Fabiana
Nov/Dec 2010
Pg. 465-471
The Clinical Use of Dehydroepiandrosterone in Postmenopausal Women
Author(s): Bramwell Bethany L
Mar/Apr 2004
Pg. 96-99
Androgen Deficiency in Women: Understanding the Science, Controversy and Art of Treating Our Patients - Part 2
Author(s): Cutter Christopher B
Jan/Feb 2013
Pg. 74-85
View Sample
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women
Author(s): Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K
Jul/Aug 2008
Pg. 295-304
Transdermal Progesterone: Effects on Menopausal Symptoms and on Thrombotic, Anticoagulant, and Inflammatory Factors in Postmenopausal Women
Author(s): Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K, Pinson Barbara, Price Carol
Sep/Oct 2007
Pg. 421
Diclofenac Sodium 75-mg/mL Injection
Author(s): Allen Loyd V Jr
May/Jun 2022
Pg. 235
Chloral Hydrate 70 mg/mL Syrup
Author(s): Allen Loyd V Jr
Jul/Aug 2018
Pg. 320
Metronidazole Benzoate 70 mg/mL in SyrSpend SF Oral Suspension
Author(s): Allen Loyd V Jr
May/Jun 2013
Pg. 234
Mercaptopurine 75-mg Capsules
Author(s): Allen Loyd V Jr
Nov/Dec 2000
Pg. 461
Progesterone Cycle Pack 35/50/75/100-mg Capsules
Author(s): Allen Loyd V Jr
May/Jun 2018
Pg. 263
Erratum: Formulation: Lansoprazole 3-mg/mL Oral Suspension
Author(s):
Jan/Feb 2001
Pg. 25
Book Reviews: Stability and Formulation References
Author(s): Allen Loyd V Jr
May/Jun 2007
Pg. 220-225
Need for Appropriate Formulations for Children: The National Institute of Child Health and Human Development--Pediatric Formulations Initiative, Part 2
Author(s): Giacoia George P, Taylor-Zapata Perdita, Mattison Donald